{"id":479,"date":"2019-01-08T16:35:37","date_gmt":"2019-01-08T15:35:37","guid":{"rendered":"https:\/\/triton.u707.jussieu.fr\/hepatherWP_test\/?p=479"},"modified":"2019-03-29T15:13:25","modified_gmt":"2019-03-29T14:13:25","slug":"actu-c","status":"publish","type":"post","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/","title":{"rendered":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs."},"content":{"rendered":"<p>Il est aujourd\u2019hui admis que le traitement de l\u2019h\u00e9patite C par antiviraux directs n\u2019augmente pas le risque de r\u00e9cidive de carcinome h\u00e9patocellulaire chez les patients ayant re\u00e7u un traitement curatif pour ce cancer. La question demeurait n\u00e9anmoins d\u2019une progression plus rapide de cette r\u00e9cidive lorsqu\u2019elle survient chez les patients recevant un traitement par antiviraux directs par rapport aux patients non trait\u00e9s. Une \u00e9tude a \u00e9t\u00e9 r\u00e9alis\u00e9e chez 39 patients de la cohorte HEPATHER atteints de r\u00e9cidive de carcinome h\u00e9patocellulaire. En utilisant une m\u00e9thodologie rigoureuse impliquant la relecture ind\u00e9pendante de tous les examens diagnostiques de la r\u00e9cidive sans information sur l\u2019existence d\u2019un traitement par antiviral direct, cette \u00e9tude montre que la vitesse de progression et le pronostic clinique chez les 17 patients ayant re\u00e7u des antiviraux directs et chez les 22 patients non trait\u00e9s sont strictement comparables.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Il est aujourd\u2019hui admis que le traitement de l\u2019h\u00e9patite C par antiviraux directs n\u2019augmente pas le risque de r\u00e9cidive de carcinome h\u00e9patocellulaire chez les patients ayant re\u00e7u un traitement curatif pour ce cancer. La question demeurait n\u00e9anmoins d\u2019une progression plus rapide de cette r\u00e9cidive lorsqu\u2019elle survient chez les patients recevant un traitement par antiviraux directs [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-479","post","type-post","status-publish","format-standard","hentry","category-actualites"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER\" \/>\n<meta property=\"og:description\" content=\"Il est aujourd\u2019hui admis que le traitement de l\u2019h\u00e9patite C par antiviraux directs n\u2019augmente pas le risque de r\u00e9cidive de carcinome h\u00e9patocellulaire chez les patients ayant re\u00e7u un traitement curatif pour ce cancer. La question demeurait n\u00e9anmoins d\u2019une progression plus rapide de cette r\u00e9cidive lorsqu\u2019elle survient chez les patients recevant un traitement par antiviraux directs [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\" \/>\n<meta property=\"og:site_name\" content=\"ANRS CO22 HEPATHER\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-08T15:35:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-29T14:13:25+00:00\" \/>\n<meta name=\"author\" content=\"admin_ft\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_ft\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\"},\"author\":{\"name\":\"admin_ft\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502\"},\"headline\":\"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs.\",\"datePublished\":\"2019-01-08T15:35:37+00:00\",\"dateModified\":\"2019-03-29T14:13:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\"},\"wordCount\":181,\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\",\"name\":\"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\"},\"datePublished\":\"2019-01-08T15:35:37+00:00\",\"dateModified\":\"2019-03-29T14:13:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"name\":\"ANRS CO22 HEPATHER\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\",\"name\":\"IPLESP UMRS 1136\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"width\":464,\"height\":175,\"caption\":\"IPLESP UMRS 1136\"},\"image\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502\",\"name\":\"admin_ft\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"caption\":\"admin_ft\"},\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_ft\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/","og_locale":"fr_FR","og_type":"article","og_title":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER","og_description":"Il est aujourd\u2019hui admis que le traitement de l\u2019h\u00e9patite C par antiviraux directs n\u2019augmente pas le risque de r\u00e9cidive de carcinome h\u00e9patocellulaire chez les patients ayant re\u00e7u un traitement curatif pour ce cancer. La question demeurait n\u00e9anmoins d\u2019une progression plus rapide de cette r\u00e9cidive lorsqu\u2019elle survient chez les patients recevant un traitement par antiviraux directs [&hellip;]","og_url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/","og_site_name":"ANRS CO22 HEPATHER","article_published_time":"2019-01-08T15:35:37+00:00","article_modified_time":"2019-03-29T14:13:25+00:00","author":"admin_ft","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin_ft","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#article","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/"},"author":{"name":"admin_ft","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502"},"headline":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs.","datePublished":"2019-01-08T15:35:37+00:00","dateModified":"2019-03-29T14:13:25+00:00","mainEntityOfPage":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/"},"wordCount":181,"publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/","name":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs. - ANRS CO22 HEPATHER","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website"},"datePublished":"2019-01-08T15:35:37+00:00","dateModified":"2019-03-29T14:13:25+00:00","breadcrumb":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/"},{"@type":"ListItem","position":2,"name":"Pas de diff\u00e9rence dans la vitesse de progression de la r\u00e9cidive de carcinome h\u00e9patocellulaire en lien avec le traitement par antiviraux directs."}]},{"@type":"WebSite","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","name":"ANRS CO22 HEPATHER","description":"","publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization","name":"IPLESP UMRS 1136","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","contentUrl":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","width":464,"height":175,"caption":"IPLESP UMRS 1136"},"image":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502","name":"admin_ft","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","caption":"admin_ft"},"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_ft\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":false,"jetpack_shortlink":"https:\/\/wp.me\/paQKc4-7J","jetpack-related-posts":[{"id":3202,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/nouvelle-publication-acceptee-2\/","url_meta":{"origin":479,"position":0},"title":"Nouvelle publication accept\u00e9e\u00a0!","author":"C\u00e9line Dorival Mouly","date":"9 septembre 2019","format":false,"excerpt":"Les travaux de Clovis Lusivika-Nzinga, \u00e9tudiant en th\u00e8se sous la direction du Pr Fabrice Carrat au sein de l\u2019unit\u00e9 INSERM U1136 \u00e0 Paris, portant sur l\u2019effet dynamique des traitements antiviraux \u00e0 action directe sur le risque de Carcinome H\u00e9patoCellulaire (CHC) chez les patients atteints d\u2019une h\u00e9patite C chronique et cirrhotique\u2026","rel":"","context":"Dans &quot;Non class\u00e9&quot;","block_context":{"text":"Non class\u00e9","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/non-classe\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3290,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","url_meta":{"origin":479,"position":1},"title":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C","author":"admin_fchau","date":"3 novembre 2019","format":false,"excerpt":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C \u00a0 A notre connaissance, l'\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d'h\u00e9patite C chronique, en comparant\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":481,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-d\/","url_meta":{"origin":479,"position":2},"title":"HEPATHER, premi\u00e8re \u00e9tude de grande ampleur en vie r\u00e9elle qui montre l\u2019efficacit\u00e9 clinique \u00e0 court terme des antiviraux directs dans l\u2019h\u00e9patite C.","author":"admin_ft","date":"8 janvier 2019","format":false,"excerpt":"Une analyse r\u00e9alis\u00e9e chez pr\u00e8s de 10,000 patients de la cohorte, documente les b\u00e9n\u00e9fices cliniques \u00e0 court terme des antiviraux \u00e0 action directe dans le traitement de l\u2019infection par le virus de l\u2019h\u00e9patite C. Avec un suivi de 33 mois en m\u00e9diane, l\u2019analyse a montr\u00e9 que le traitement de l\u2019h\u00e9patite\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3303,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","url_meta":{"origin":479,"position":3},"title":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!","author":"admin_fchau","date":"23 novembre 2021","format":false,"excerpt":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l'identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l'h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3393,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2024-une-annee-de-preparation-et-de-transition-3-publications-par-lequipe-du-sesstim\/","url_meta":{"origin":479,"position":4},"title":"2024 &#8211; une ann\u00e9e de pr\u00e9paration et de transition. 3 publications par l&rsquo;\u00e9quipe du SESSTIM.","author":"admin_fchau","date":"17 mars 2025","format":false,"excerpt":"L'ann\u00e9e 2024 a \u00e9t\u00e9 marqu\u00e9e par la pr\u00e9paration de la suite de la cohorte HEPATHER dont la date de fin \u00e9tait programm\u00e9e au 31 d\u00e9cembre 2024.Hepat-B proposera de prolonger le suivi des patients atteints d'h\u00e9patite B inclus dans Hepather jusqu'en 2029, avec la r\u00e9alisation de nouvelles collections biologiques. Cette cohorte\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3372,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2022-15-travaux-publies-a-partir-des-donnees-de-la-cohorte-hepather\/","url_meta":{"origin":479,"position":5},"title":"2022. 15 travaux publi\u00e9s \u00e0 partir des donn\u00e9es de la cohorte HEPATHER !","author":"admin_fchau","date":"17 d\u00e9cembre 2022","format":false,"excerpt":"Ces \u00e9tudes apportent des avanc\u00e9es importantes dans la compr\u00e9hension des h\u00e9patites virales B et C et de leurs complications, notamment en mati\u00e8re de d\u00e9pistage pr\u00e9coce, de facteurs de risque et de strat\u00e9gies pr\u00e9ventives.Plusieurs \u00e9tudes r\u00e9alis\u00e9es par l'\u00e9quipe de sciences sociales du SESSTIM (Inserm, Universit\u00e9 Aix Marseille et IRD) ont port\u00e9\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/comments?post=479"}],"version-history":[{"count":1,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/479\/revisions"}],"predecessor-version":[{"id":3029,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/479\/revisions\/3029"}],"wp:attachment":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/media?parent=479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/categories?post=479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/tags?post=479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}